Enoximone: Difference between revisions

	WikiDoc Resources for Enoximone
Articles
Most recent articles on Enoximone Most cited articles on Enoximone Review articles on Enoximone Articles on Enoximone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Enoximone Images of Enoximone Photos of Enoximone Podcasts & MP3s on Enoximone Videos on Enoximone
Evidence Based Medicine
Cochrane Collaboration on Enoximone Bandolier on Enoximone TRIP on Enoximone
Clinical Trials
Ongoing Trials on Enoximone at Clinical Trials.gov Trial results on Enoximone Clinical Trials on Enoximone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Enoximone NICE Guidance on Enoximone NHS PRODIGY Guidance FDA on Enoximone CDC on Enoximone
Books
Books on Enoximone
News
Enoximone in the news Be alerted to news on Enoximone News trends on Enoximone
Commentary
Blogs on Enoximone
Definitions
Definitions of Enoximone
Patient Resources / Community
Patient resources on Enoximone Discussion groups on Enoximone Patient Handouts on Enoximone Directions to Hospitals Treating Enoximone Risk calculators and risk factors for Enoximone
Healthcare Provider Resources
Symptoms of Enoximone Causes & Risk Factors for Enoximone Diagnostic studies for Enoximone Treatment of Enoximone
Continuing Medical Education (CME)
CME Programs on Enoximone
International
Enoximone en Espanol Enoximone en Francais
Business
Enoximone in the Marketplace Patents on Enoximone
Experimental / Informatics
List of terms related to Enoximone

Enoximone
Clinical data
Routes of; administration	Intravenous
ATC code	C01CE03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only) ;
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Hepatic oxidation
Elimination half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
	IUPAC name 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-; dihydroimidazol-2-one;
CAS Number	77671-31-9;
PubChem CID	53708;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C12H12N2O2S
Molar mass	248.302 g/mol
3D model (JSmol)	Interactive image;
	SMILES CSc1ccc(cc1)C(=O)C2=C(C)NC(=O)N2;

Latest revision as of 20:35, 24 July 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.^[1]

↑ Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother. 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID 17714066.

@@ Line 25: / Line 25: @@
 }}
 __NOTOC__
+{{SI}}
 {{CMG}}
 ==Overview==
-'''Enoximone''' ([[International Nonproprietary Name|INN]], trade name '''Perfan''') is an [[imidazole]] [[phosphodiesterase inhibitor]]. It is used in the treatment of [[congestive heart failure]].
+'''Enoximone''' ([[International Nonproprietary Name|INN]], trade name '''Perfan''') is an [[imidazole]] [[phosphodiesterase inhibitor]]. It is used in the treatment of [[congestive heart failure]].<ref name="pmid17714066">{{cite journal |author=Boldt J, Suttner S |title=Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone |journal=Expert Opin Pharmacother |volume=8 |issue=13 |pages=2135–47 |date=September 2007 |pmid=17714066 |doi=10.1517/14656566.8.13.2135 |url=}}</ref>
+==References==
+{{reflist|2}}
 {{Phosphodiesterase inhibitors}}
 {{Cardiac stimulants excluding cardiac glycosides}}
-[[Category:Aromatic hydrocarbons]]
+[[Category:Cardiovascular Drugs]]
-[[Category:Imidazoles]]
+[[Category:Drug]]
 [[Category:Phosphodiesterase inhibitors]]
-[[Category:Thioethers]]
-[[Category:Cardiovascular drugs]]
-[[Category:Drugs]]
-[[uk:Еноксімон]]
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}

Clinical data

Routes of administration	Intravenous
ATC code	C01CE03 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Hepatic oxidation
Elimination half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
IUPAC name 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3- dihydroimidazol-2-one
CAS Number	77671-31-9
PubChem CID	53708
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₂H₁₂N₂O₂S
Molar mass	248.302 g/mol
3D model (JSmol)	Interactive image
SMILES CSc1ccc(cc1)C(=O)C2=C(C)NC(=O)N2